Lung Therapeutics, Inc. Online Press Kit Lung Therapeutics, Inc. Raises $14.3 Million Series B Financing to Treat Unmet Needs in Lung Disease and Fibrosis Financing will support further development of the Company’s LTI-03 transformative drug technology and the current multi-site clinical trial of orphan drug LTI-01. Tue, 06 Jun 2017 06:00:00 -0400 Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand LTI-01 addresses unmet needs in a $600+ million global market. Intended to replace costly surgery and ineffective off-label treatments of fibrosis, the drug can provide safer and more cost-effective therapeutic options for CPE/empyema patients and healthcare providers worldwide. Tue, 14 Mar 2017 18:14:00 -0400 LUNG THERAPEUTICS, INC. RECEIVES FDA ORPHAN DRUG DESIGNATION FOR LEAD DRUG CANDIDATE LTI-01 Tue, 02 Dec 2014 18:21:00 -0500 PHARMA START-UP LUNG THERAPEUTICS, INC. ACHIEVES SIGNIFICANT FUNDING TO ADDRESS UNMET NEEDS IN LUNG INJURY AND DISEASE Tue, 28 Oct 2014 18:22:00 -0400